Identifying and Managing Hepatitis B in Special Patient Populations: A Clinical and Cost Analysis

Interactive Case Vignettes

Sponsored by North American Center for Continuing Medical Education, LLC

Faculty

Adrian M. Di Bisceglie, MD, FACP
Chairman, Internal Medicine
Chief of Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri

Roderick Boone, MHP, RPh
Senior Director, Pharmacy Services
MedVentive Inc.
Waltham, Massachusetts
Adjunct Assistant Clinical Professor
Department of Pharmacy Practice
Northeastern University
Boston, Massachusetts

Target Audience

This activity is designed for managed markets physicians and pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

• Chart the patient populations with significant hepatitis B virus (HBV) risk and prevalence and list considerations for screening and management
• Describe the clinical and economic impact of HBV infection, including disease progression and complications
• Outline the impact of standard and newer therapies on improving outcomes and reducing viral replication and drug resistance
• Apply evidence-based guidelines to support best practices in HBV management across special patient populations

Activity Overview

Interactive case vignette activities consist of 4 patient case studies with polling questions integrated throughout.

To be eligible for documentation of credit, participants must complete 4 case studies, answer all polling questions, and complete the evaluation form. After successful completion of the evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

Release Date: December 30, 2009

Expiration Date: December 30, 2010

Estimated time to complete: 1 hour

For questions regarding this educational activity, please contact Angela Scarnici at 609-371-1137.

Hardware/Software Requirements

All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

This educational activity is an application-based activity.

CME Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

CPE Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 276-000-09-041-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact John Savage, Director, Medical Education, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535, or by e-mail at jsavage@naccme.com. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Walid Ayoub, MD, Clinical Associate Professor of Medicine, Department of Gastroenterology and Hepatology, Stanford University, Palo Alto, California

Planning Committee

The planning committee comprises: Adrian M. Di Bisceglie, MD, FACP; Roderick Boone, MHP, RPh; Walid Ayoub, MD; Donna Kruggel, Nick Lombardi, Emilie McCardell, James Meringer, Randy Robbin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
                
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:
Dr. Di Bisceglie: Advisory Board–Anadys Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlobeImmune Inc., Idenix Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Roche, Vertex Pharmaceuticals; Consultant–Abbott, Bristol-Myers Squibb Company, Pharmasset Inc., Schering Plough; Speakers’ Bureau–Novartis Pharmaceuticals Corporation; Research Support–Bristol-Myers Squibb Company, Gilead Sciences, GlobeImmune Inc., Idenix Pharmaceuticals, Roche, Vertex Pharmaceuticals
Mr. Boone has disclosed no relevant financial relationships with any commercial interests.
Dr. Ayoub: Scientific Advisor–Gilead Sciences, Schering Plough; Speakers’ Bureau–Roche; Research Support–Cangene Corporation

Ms. Kruggel, Mr. Lombardi, Ms. McCardell, Mr. Meringer, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed the following off-label/unapproved use(s) of drugs and/or devices will be discussed: The use of the combination of tenofovir and emtricitabine for the treatment of hepatitis B; the use of emtricitabine monotherapy for the treatment of hepatitis B.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2009 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support

Supported by an educational grant from Bristol-Myers Squibb Company